Royalty Pharma plc (RPRX) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for Royalty Pharma plc (RPRX): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 59/100 — a percentile rank of Royalty Pharma plc’s fundamentals against Manufacturing peers, weakest on financial health. A quality ranking, not a price prediction.
| Market cap | $26.0B |
| P / E | 31.9× |
| P / S | 10.2× |
| EV / EBITDA | 20.0× |
| Gross margin | 100.0% |
| Operating margin | 59.6% |
| Net margin | 53.2% |
| Return on equity | 11.9% |
| ROIC | 8.4% |
| Revenue growth | 10.0% |
| Debt / equity | 1.3× |
| Dividend yield | 1.5% |
Is Royalty Pharma plc overvalued? P/E looks fair vs its 5-year range; P/S looks overvalued vs its 5-year range; EV/EBITDA looks overvalued vs its 5-year range; P/B looks overvalued vs its 5-year range.
Independent of the events above — derived from Royalty Pharma plc’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact